#USA #Carlsbad #Active Motif #Arima Genomics #Hi-C Technology

Active Motif and Arima Genomics Join Forces in Exclusive Global Distribution Agreement

On July 7, 2026, Active Motif, a prominent provider of epigenetic and multi-omic solutions for mechanistic, translational, and clinical researchers, announced a strategic partnership with Arima Genomics. This collaboration marks an exclusive global distribution agreement, aimed at advancing the field of 3D genomics.

As the exclusive distributor of Arima's Hi-C products and services for research applications, Active Motif will expand its existing portfolio, aligning with Arima's focus on enhancing its clinical diagnostic platform, Aventa. The agreement showcases Active Motif's commitment to meeting the increasing demands for technologies that elucidate how genomic structure affects gene regulation, cellular function, and disease biology.

The realm of genomic research has seen significant evolution, moving beyond traditional sequence-based analyses. Technologies like Hi-C represent a critical advancement, enabling researchers to explore chromatin organization, structural variation, enhancer-promoter interactions, and genome-wide regulatory mechanisms. Such insights are invaluable across various fields, including oncology, neuroscience, developmental biology, rare disease research, and precision medicine.

Joe Fernandez, the President and founder of Active Motif, expressed enthusiasm about the partnership, stating, "This agreement cements Active Motif's position as a leading provider of integrated multi-omic solutions. Researchers are increasingly seeking comprehensive insights into genome function that integrates chromatin accessibility, transcription factor binding, epigenetic regulation, gene expression, and genome architecture. By incorporating Arima's industry-leading Hi-C technology into our product suite, we enhance our capacity to deliver comprehensive solutions that address critical questions in modern biology."

The collaboration further solidifies Active Motif's rapidly growing portfolio of genomic and epigenomic technologies, which includes products and services for chromatin analysis, transcriptional regulation, and next-generation sequencing applications. The addition of Hi-C technology improves Active Motif's ability to cater to burgeoning markets in spatial genomics and 3D biology while opening new avenues for integrated multi-omic research workflows.

Dr. Tom Willis, CEO of Arima Genomics, shared insights on the partnership, highlighting the synergy between the two companies: "At Arima, we are focused on leveraging the significant opportunity for our Aventa clinical diagnostic platform, where we combine DNA sequencing and structure to uncover alterations driving cancer from routine FFPE tumor samples. This agreement aligns our Hi-C research technologies with Active Motif's highly complementary portfolio, commercial infrastructure, scientific expertise, and long-standing relationships with the research community."

This exclusive distribution agreement combines Arima's leadership in 3D genomic solutions with Active Motif's established global commercial organization and technical support capabilities. This strategic alignment boosts access for academic, pharmaceutical, biotech, and clinical research organizations to these advanced technologies.

Effective immediately, researchers can order Arima's Hi-C products and services for research applications globally through Active Motif.

About Active Motif

Active Motif is a leading provider of epigenetic, genomic, and multi-omic solutions that empower researchers to study gene regulation, chromatin biology, and disease mechanisms. Through innovative products, services, and scientific expertise, Active Motif supports researchers worldwide in advancing discoveries that improve human health.

About Arima Genomics

Arima Genomics is a pioneering oncology diagnostics company redefining cancer detection testing by integrating DNA sequence and structure. With strong expertise in 3D genomic science and Hi-C sequencing technology, Arima develops clinical tests that reveal alterations driving cancer, often missed or inadequately characterized by conventional methods. Through its clinical testing brand, Aventa, Arima offers tests for solid tumors and lymphoma from its CLIA-certified lab in Orlando, Florida. For more information, visit www.arimagenomics.com and aventatest.com.